2002
Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial
Cushman M, Costantino J, Bovill E, Wickerham D, Buckley L, Roberts J, Krag D. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. British Journal Of Haematology 2002, 120: 109-116. PMID: 12492585, DOI: 10.1046/j.1365-2141.2003.03976.x.Peer-Reviewed Original ResearchConceptsBreast Cancer Prevention TrialVenous thrombosis risk factorsActivated protein CEffects of tamoxifenCancer Prevention TrialThrombosis risk factorsRisk factorsProtein CProtein SVenous thrombosisTamoxifen reduces breast cancer incidenceIncreased riskIncreased risk of venous thrombosisPrevention trialsActivated protein C resistanceRisk of venous thrombosisPlacebo-treated womenReduction of antithrombinTamoxifen-treated womenDouble-blind fashionMonths of treatmentActivated protein C ratioBreast cancer incidenceProtein C antigenBody mass index
2001
Tamoxifen and Cardiac Risk Factors in Healthy Women
Cushman M, Costantino J, Tracy R, Song K, Buckley L, Roberts J, Krag D. Tamoxifen and Cardiac Risk Factors in Healthy Women. Arteriosclerosis Thrombosis And Vascular Biology 2001, 21: 255-261. PMID: 11156862, DOI: 10.1161/01.atv.21.2.255.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnti-Inflammatory AgentsAntineoplastic Agents, HormonalBlood CoagulationBreast NeoplasmsC-Reactive ProteinCardiovascular DiseasesCardiovascular SystemCholesterolDouble-Blind MethodFemaleFibrinogenHumansPlacebosPostmenopauseRisk FactorsSelective Estrogen Receptor ModulatorsTamoxifenConceptsEffects of tamoxifenBreast Cancer Prevention TrialIncidence of breast cancerCardiovascular disease risk factorsHigh waist-to-hip ratioWaist-to-hip ratioHealthy womenDisease risk factorsRisk factorsCancer Prevention TrialAssociated with venous thrombosisFactor VII coagulant activityAssociation of tamoxifenFactors related to inflammationEffects of oral tamoxifenCardiac risk factorsC-reactive proteinVII coagulant activitySecondary analysisPrevention trialsMedian fibrinogenOral tamoxifenPostmenopausal womenPostmenopausal estrogenVenous thrombosis
1997
A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group.
Tuttleman M, Pillemer S, Tilley B, Fowler S, Buckley L, AlarcĂłn G, Trentham D, Neuner R, Clegg D, Leisen J, Heyse S. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group. The Journal Of Rheumatology 1997, 24: 1910-5. PMID: 9330931.Peer-Reviewed Original ResearchConceptsPatient global assessmentSF-36Rheumatoid arthritisM-HAQOutcome measuresClinical trialsGlobal assessmentShort Form Health SurveyFunctional health status measuresJoint swelling scoreRA clinical trialsRA outcome measuresHealth Assessment QuestionnaireHealth status instrumentsSF-36 scalesRheumatoid arthritis trialsHealth status measuresMultitrait scaling analysisCross-sectional assessmentCross-sectional analysisMIRA trialStudy patientsRA populationScore correlationsPain items
1996
Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial.
Buckley L, Leib E, Cartularo K, Vacek P, Cooper S. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Annals Of Internal Medicine 1996, 125: 961-8. PMID: 8967706, DOI: 10.7326/0003-4819-125-12-199612150-00004.Peer-Reviewed Original ResearchConceptsBone mineral densityLow-dose corticosteroidsPlacebo-controlled trialVitamin D3 supplementationMineral densityRheumatoid arthritisVitamin D3Prednisone therapyLumbar spineD3 supplementationBone lossOutpatient care facilitiesLong-term useCorticosteroid useVertebral fracturesWard's triangleAutoimmune diseasesFemoral neckCorticosteroidsHigh riskSupplemental calciumRational therapyPatientsArthritisTherapy
1995
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
Tilley B, Alarcon G, Heyse S, Trentham D, Neuner R, Kaplan†D, Clegg D, Leisen J, Buckley L, Cooper S, Duncan H, Pillemer S, Tuttleman M, Fowler S. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Annals Of Internal Medicine 1995, 122: 81-9. PMID: 7993000, DOI: 10.7326/0003-4819-122-2-199501150-00001.Peer-Reviewed Original ResearchConceptsIgM rheumatoid factor levelsErythrocyte sedimentation rateRheumatoid factor levelsRheumatoid arthritisMinocycline groupGlobal assessmentPlacebo groupMore patientsPlatelet countModified Health Assessment QuestionnaireFactor levelsEfficacy of minocyclineEvaluator's global assessmentWeek 48 visitActive rheumatoid arthritisHealth Assessment QuestionnairePatient global assessmentPlacebo-controlled trialModerate rheumatoid arthritisDisease-modifying drugsMechanism of actionJoint tendernessMorning stiffnessStudy medicationDisease activity
1990
Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis.
Buckley L, Vacek P, Cooper S. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. The Journal Of Rheumatology 1990, 17: 1158-61. PMID: 2132565.Peer-Reviewed Original ResearchConceptsLow-dose methotrexateFolinic acidDose methotrexateRheumatoid arthritisShort-term side effectsDose of methotrexateIncidence of stomatitisFolinic acid supplementationTerm side effectsLeucovorin treatmentAntiarthritic effectsGastrointestinal toxicityMTX administrationCrossover trialTherapeutic effectAcid supplementationSide effectsMethotrexateLeucovorinArthritisSignificant differencesPatientsAdministrationDosePlacebo
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply